NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening

NuVasive, Inc. (NASDAQ: NUVA) today announced a milestone of more than 100 peer-reviewed publications of the Precice® System (Precice) for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™ (NSO). The Precice System is an intramedullary nail that once implanted, utilizes an External Remote Controller (ERC) to non-invasively lengthen the limb.

“This significant milestone further supports the benefits that Precice offers orthopedic surgeons and their patients,” said Dr. Stuart Green, orthopedic surgeon at UC Irvine School of Medicine. “First introduced in 2011, Precice has been used to successfully overcome limb length deficiencies in thousands of patients around the world with less pain and fewer complications than previously thought possible. The publications demonstrate the important role the implant plays in modern limb reconstruction—helping establish Precice as today’s standard of care.”

Following the first publication in 2014 in Clinical Orthopaedics and Related Research,1 more than 100 peer-reviewed publications have been authored in countries including the United States, Germany, and South Africa. Precice has been researched in dozens of journals including The Journal of Bone and Joint Surgery, Journal of Orthopaedic Trauma, Journal of the American Academy of Orthopaedic Surgeons, and The Journal of Surgical Orthopaedic Advances.

“With approximately 15,000 procedures in more than 45 countries, today’s announcement is yet another significant milestone for Precice,” said Pete Ligotti, general manager of NSO. “We remain committed to providing novel technology in underserved markets to help deliver better outcomes for surgeons—and most importantly for patients.”

NSO, a division of NuVasive, is focused on the design and innovation of disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening. Precice is used to treat long bone abnormalities resulting from congenital bone conditions, oncology, or trauma. The proprietary technology includes a complex 60-piece internal gear system remotely activated and controlled by permanent rare earth magnets. This advancement in limb lengthening allows for a precision-controlled distraction phase with the ability to non-invasively customize treatment to best treat the patient’s individual needs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”